Sign Out
Administration of dibekacin may cause impairment of the auditory portion of the 8th nerve with symptoms eg, vertigo, tinnitus and hearing difficulty. Close observation for the signs of impairment is needed during therapy. It is desirable to discontinue administration once symptoms have occurred. In case continuous administration is inevitable, Dibekacin Meiji Injection should be given under careful observation.
Administration of dibekacin may rarely cause disturbance in liver or kidney function. Close observation for the disturbance is needed during therapy. If there is evidence of abnormality, administration should be discontinued. In case dibekacin is given to patients with impaired kidney function or to older patients, careful observation is needed.
The concurrent administration of blood substitutes eg, dextran and sodium alginate, should be avoided because of the possibility of intensifying the effects of these nephrotoxic drugs.
In case hypersensitivity reactions have occurred during therapy, administration should be discontinued. Dibekacin Meiji Injection should not be given to patients with history of hypersensitivity to aminoglycoside antibiotics eg, fradiomycin (neomycin), amikacin, kanamycin, streptomycin and gentamicin, and to bacitracin.
It is desirable to avoid administration to patients with past or family history of streptomycin- or any other drug-induced hearing difficulty. In case administration of dibekacin is inevitable, it should be given under careful observation.
Administration of dibekacin may cause respiratory depression due to its neuromuscular-blocking effect. Combined use with anesthetics or muscle-relaxing drugs should be carefully practiced.
Caution should be exercised in patients with poor oral nutrition.
Dibekacin Meiji Injection is for IM use and IV drip infusion.
Use in pregnancy: Administration to pregnant women may cause impairment of the auditory portion of the 8th nerve of their neonates. Dibekacin Meiji Injection should be given under careful observation.
